| Literature DB >> 21511783 |
Merrick Zwarenstein1, Lara R Fairall, Carl Lombard, Pat Mayers, Angeni Bheekie, René G English, Simon Lewin, Max O Bachmann, Eric Bateman.
Abstract
OBJECTIVE: To investigate whether PALSA PLUS, an on-site educational outreach programme of non-didactic, case based, iterative clinical education of staff, led by a trainer, can increase access to and comprehensiveness of care for patients with HIV/AIDS.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21511783 PMCID: PMC3080737 DOI: 10.1136/bmj.d2022
Source DB: PubMed Journal: BMJ ISSN: 0959-8138

Fig 1 Comparison of ART specialist training and PALSA PLUS outreach approach

Fig 2 Details of clinic selection, allocation, enrolment, and follow-up in trial (IQR=interquartile range)
Characteristics of clinics and patients according to additional outreach intervention or usual care in decentralising HIV/AIDS/ART programme. Figures are numbers (percentages) unless stated otherwise
| Outreach group | Control group | |
|---|---|---|
| No of clinics | 8 | 7 |
| Median quarterly adult attendances | 8929 | 7236 |
| Median No of nurses per clinic | 11 | 9 |
| Median distance from referral site (km) | 25 | 25 |
| No of patients | 5523 | 4210 |
| Sex (women) | 3576/5521 (65) | 2764 (66) |
| Mean age (years) | 35.4 | 35.6 |
| Any previous antiretroviral treatment | 59 (1) | 39 (1) |
| CD4 count at enrolment (cells/μl): | ||
| Median (IQR) | 166 (71-319) | 185 (84-339) |
| <25 | 388 (7) | 278 (7) |
| 25-49 | 344 (6) | 219 (5) |
| 50-99 | 615 (11) | 427 (10) |
| 100-199 | 1064 (19) | 758 (18) |
| 200-349 | 798 (14) | 725 (17) |
| ≥350 | 892 (16) | 749 (18) |
| Unknown | 1422 (26) | 1054 (25) |
| Mean weight at enrolment (kg) | 56.7 | 57.0 |
| WHO stage at doctor assessment: | ||
| Stage 1/2 | 761/1815 (42) | 435/1359 (32) |
| Stage 3/4 | 1057/1815 (58) | 924/1359 (68) |
| Employed | 127/1014 (13) | 102/1044 (10) |
| Median (IQR) household size | 4 (3-6) | 4 (3-6) |
| Household receiving social welfare | 445/1006 (44) | 500/1027 (49) |
IQR=interquartile range.
Trial outcomes in intervention clinics (with added PALSA PLUS outreach education) and control clinics (with specialist ART nurse training only)
| No (%, SD, or IQR) | OR, HR, MD, or IRR* (95% CI) | P value | Intracluster correlation coefficient | ||
|---|---|---|---|---|---|
| Intervention clinics | Control clinics | ||||
| Enrolment in programme through new HIV testing (1 year)† | 3048/5793 (53%) | 2187/4343 (50%) | OR 1.19 (0.51 to 2.77) | 0.695 | 0.108 |
| Provision of co-trimoxazole prophylaxis over 12 months | 2253/5523 (41%) | 1340/4210 (32%) | OR 1.95 (1.11 to 3.40) | 0.020 | 0.034 |
| Tuberculosis case detection† | 417/5793 (7%) | 245/4343 (6%) | OR 1.25 (1.01 to 1.55) | 0.038 | 0.027 |
| Viral load suppressed after 6 months’ antiretroviral treatment | 332/389 (85%) | 332/389 (88%) | OR 0.96 (0.74 to 1.26) | 0.779 | 0.088 |
| Mortality | 958/4754 (20%) | 792/3645 (22%) | HR 0.90 (0.67 to 1.19) | 0.466 | NA |
| CD4 follow-up among patients with initial CD4 200-500 cells/μl | 1127/1276 (88%) | 954/1141 (84%) | OR 1.39 (0.65 to 2.96) | 0.40 | 0.022 |
| Weight gain (kg) | 2.3 (SD 5.8) | 1.9 (SD 6.1) | MD 0.55 (0.30 to 0.79) | <0.001 | 0.10 |
| Clinic visits | 6 (IQR 3-15) | 8 (IQR 4-19) | IRR 0.95 (0.77 to 1.18) | 0.658 | 0.026 |
| Enrolment in programme through new HIV testing (1 month) * | 357/653 (55%) | 214/499 (43%) | OR 1.58 (1.01 to 2.48) | 0.054 | 0.113 |
| Provision of co-trimoxazole prophylaxis to patients with ≤200 CD4 cells/μl, AIDS, or tuberculosis | 1762/2419 (73%) | 1025/1572 (65%) | OR 1.88 (1.07 to 3.31) | 0.029 | 0.035 |
IQR=interquartile range.
*OR=odds ratio; HR=hazard ratio; MD=mean difference; IRR=incidence rate ratio.
†Denominator includes all patients enrolled in treatment programme, as well as patients who were tested through programme with negative results.